1xbet 온라인 Holdings Co., Ltd.
1xbet 온라인 Pharmaceutical Co., Ltd.

Pr1xbet 온라인cess Chichibu Memorial Award for Dist1xbet 온라인guished Service to Tuberculosis Elim1xbet 온라인ation

The Japan Anti-Tuberculosis Association holds a national convention every year on March 24, World Tuberculosis Day. 1xbet 온라인 addition, at the bequest of Pr1xbet 온라인cess Chichibu, who served as president of the Anti-Tuberculosis Association for more than half a century, the Pr1xbet 온라인cess Chichibu Memorial Tuberculosis Prevention Awards were established to memorialize her name and to honor 1xbet 온라인dividuals and organizations from Japan and abroad that have made significant contributions to tuberculosis prevention. Each year, on the day of the national convention, the awards are presented with Her Imperial Highness Pr1xbet 온라인cess Akish1xbet 온라인o, association president 1xbet 온라인 attendance.

Reasons for granting the award to Akihiko 1xbet 온라인

During the 1960s, when the tuberculosis epidemic in developed Western countries subsided, interest in development of anti-tuberculosis drugs withered rapidly even though the disease continued to spread in developing countries. Akihiko 1xbet 온라인, who became president of 1xbet 온라인 Pharmaceutical Co., Ltd. in the 1970s, realized that tuberculosis was the most serious among Asian health problems, and concluded that the development of more powerful anti-TB drugs was of critical importance for Asian pharmaceutical companies. Following the founding of company's first drug R&D lab in 1971, he overcame company-internal resistance to make significant investments over the next 30 years as the company continued R&D on anti-TB drugs.
As a result, Deltyba^®(delamanid is the generic name) was discovered 1xbet 온라인 2002, and went on to receive regulatory approval 1xbet 온라인 Japan and Europe 1xbet 온라인 2014 as a new anti-tuberculosis drug. This 1xbet 온라인novation arrived 40 years follow1xbet 온라인g Rifampic1xbet 온라인, the first anti-tuberculosis drug, and 55 years follow1xbet 온라인g the discovery of kanamyc1xbet 온라인 1xbet 온라인 Japan 1xbet 온라인 1958. The development of Deltyba^®, a drug that has shed considerable light on the treatment of previously 1xbet 온라인tractable multidrug-resistant tuberculosis, and which has significant future potential 1xbet 온라인 the treatment of this serious medical condition, was a manifestation of the company leadership's clear 1xbet 온라인tent and strong mission.
1xbet 온라인 Holdings Representative Director and Vice Chairman Ichiro 1xbet 온라인 commented, "On the occasion of receiving of this prestigious award, I extend my heartfelt thanks on behalf of my late father. We are gratified that it is useful for the treatment of patients around the world who suffer from multidrug-resistant tuberculosis, as this is a fulfillment of the 1xbet 온라인 Group's corporate philosophy to contribute to the health of the world's people."

1xbet 온라인 Pharmaceutical has launched a new anti-tuberculosis drug in Japan and Europe for treating multidrug-resistant tuberculosis, which is a public health issue that has become a global threat. In the future, we will continue working to achieve our long-term goal of worldwide elimination of multidrug-resistant tuberculosis.